Ensuring Access to Essential Drugs Act
Summary
HR1922 is an early-stage bill referred to committee with no market impact. It would exempt certain orally administered brand-name drugs from Medicare Part D rebate obligations, but no hearings, votes, or further action have occurred since introduction on 2025-03-06.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1922 is in the earliest legislative stage with no momentum.
- 2.The exemption applies only to a narrow subset of drugs with a specific CMS reclassification — no affected drugs or companies are identifiable from the bill text.
- 3.No immediate market impact; the bill is purely procedural at this point.
Market Implications
No market implications at this stage. The bill does not name any companies, authorize spending, or create a clear revenue mechanism for any publicly traded entity. Retail investors should not adjust positions based on this bill alone.
Full Analysis
- HR1922, the 'Ensuring Access to Essential Drugs Act,' was introduced on March 6, 2025 by Rep. Garbarino (R-NY) with two cosponsors. It has been referred to both the Energy and Commerce and Ways and Means Committees. No further actions have occurred. 2) The bill does not authorize or appropriate any funding. It modifies the Medicare Part D Manufacturer Discount Program to exempt specific orally administered brand-name drugs that have been reclassified as noninnovator multiple source drugs under Medicaid. This is a regulatory exemption, not a spending bill. 3) No specific publicly traded companies are directly named in the bill text. The exemption would apply to a narrow, undefined set of drugs requiring a CMS exception. Without knowing which drugs or manufacturers hold such exceptions, no ticker-level analysis is possible. 4) The bill has zero legislative velocity — two committee referrals on the same day and no actions since. No companion bill in the Senate. 5) Next steps would require committee hearings, markup, floor votes in both chambers, and presidential action. Given the early stage and narrow scope, meaningful market impact is years away if it advances at all.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Ensuring Access to Lower-Cost Medicines for Seniors Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →